Canadian Bio Med Attacks World's Leading Cause of Blindness

NEW YORK, MONTREAL and SAN DIEGO, CA, June 30 /PRNewswire-FirstCall/ -
Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and
Ocular Therapeutics Inc. of San Diego California, announced the development of
a new AMD drug now being tested by Canadian Bio Med Systems, Inc. (CBMS).
Age-Related Macular Degeneration (AMD) is the leading cause of blindness,
worldwide, for people over 55 years of age. The incidence of AMD in persons
aged 55 is 1% and increases to 15% for persons aged 80. This debilitating
disease has proven to be difficult to treat and only a very few drugs have
been developed which have positive effects.
The drug under development by Canadian Bio Med Systems, has a very different
mode of action than the current therapeutic products. It can be used alone or
in conjunction with these currently available products.
The product under development by CBMS, LD22-4 has the advantage of being a
very small molecule meaning that fewer treatments will be needed compared to
current therapies, This will help reduce the pain and frequency of injection
to the patient and potentially the cost of the treatment.
Canadian Bio Med is developing the new product in Quebec in conjunction with
its partner, Ocular Therapeutics Inc. of San Diego, California. The drug is
moving toward human clinical trials in Canada and the United States next year.
The market for products treating AMD has been estimated at over $750 million
annually and growing at a rate of over 10% yearly as the population ages.

NB. This news release includes statements that constitute forward-looking
statements. Please be aware that any such forward-looking statements are not
guarantees of future performance and involve significant risks and
uncertainties, and that actual results may vary materially from those in the
forward-looking statements as a result of any number of factors, including the
risk factors contained in the Company's disclosure documents.
SOURCE Inter Canadian Business Service

Randy Bailey, (949) 228-4258; Source: Ocular Therapeutics Inc.